DCF — ST. FRANCIS BARTLETT MED CTR
Enterprise Value: $-5.2M
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
$-5.2M
Enterprise Value
$-5.0M
PV of Cash Flows
$-0.2M
PV of Terminal Value
$-0.4M
Terminal Value
10.0%
WACC
2.5%
Terminal Growth
Cash Flow Projections
PROJ| Year | Revenue | EBITDA | Margin | FCF | PV(FCF) |
|---|---|---|---|---|---|
| Year 1 | $133.1M | $2.7M | 2.0% | $-2.9M | $-2.7M |
| Year 2 | $137.1M | $4.2M | 3.0% | $-1.8M | $-1.5M |
| Year 3 | $141.2M | $5.7M | 4.0% | $-0.8M | $-0.6M |
| Year 4 | $145.5M | $6.6M | 5.0% | $-0.3M | $-0.2M |
| Year 5 | $149.8M | $7.2M | 5.0% | $-0.0M | $-0.0M |
Interpretation
INTAt a WACC of 10.0% and terminal growth of 2.5%, enterprise value is $-5.2M. Terminal value accounts for 0% of total EV — consider sensitivity to terminal assumptions.
Next steps: Check the LBO model to see equity returns at this entry price, or the EBITDA bridge to model value creation levers.
Assumptions
ASSMrevenue base$129.2M
revenue growth rates[0.03, 0.03, 0.03, 0.03, 0.03]
ebitda margin base0.015371912296404751
ebitda margin improvement bps[50, 100, 100, 50, 25]
capex pct revenue0.04
nwc pct revenue0.08
tax rate0.25
projection years5